Open Access<p>Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis</p>
Author(s) -
Nancy Mahler,
B Turner,
Michael Eaddy,
Mark L. Hanke,
Winnie W. Nelson
Publication year - 2020
Publication title -
open access rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.63
H-Index - 14
ISSN - 1179-156X
DOI - 10.2147/oarrr.s231667
Subject(s) - medicine , polymyositis , rheumatoid arthritis , dermatomyositis , demographics , medical record , exacerbation , medical prescription , connective tissue disease , retrospective cohort study , hydroxychloroquine , systemic lupus erythematosus , dermatology , autoimmune disease , disease , demography , covid-19 , sociology , infectious disease (medical specialty) , pharmacology
Repository corticotropin injection (RCI) is indicated for a number of autoimmune-mediated diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis (DM)/polymyositis (PM). To better understand the practice patterns and outcomes of RCI in patients with RA, SLE, or DM/PM, we conducted a retrospective medical record analysis.